Panaccione R, et al. - In patients with Crohn’s disease (CD) naïve to immunosuppressants and biologics, researchers assessed the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) vs symptom-based clinical management (CM), using a UK public payer perspective. Based on the Effect of Tight Control Management on Crohn’s Disease (CALM) trial, weekly CD Activity Index (CDAI)-based transition matrices (remission: CDAI <150, moderate: CDAI ≥150 to <300, severe: CDAI ≥300 to <450, very severe: CDAI ≥450) were estimated via a regression model. Findings revealed the cost-effectiveness of a TC strategy as used in the CALM trial, vs CM. The economic value of TC is increased by including expenses associated with work productivity. As differences in healthcare systems exist, exercising caution while making cross-national inferences from this analysis is recommended.